An interventional study of Diagnostic Test: serology test for COVID-19 in Covid19, sponsored by Hôpital Européen Marseille. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Hôpital Européen Marseille · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 782 studies in COVID-19 with a site in France — 51 open to participants now, 68 under way, 7 of them phase 3. COVID-19 · France.
Among the 782 studies in COVID-19 with a site in France, this one is the 114th largest by enrollment of the 294 interventional ones that give a count, is one of 499 that started in 2020, is one of 178 with no phase, and was the 342nd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →51 of the 782 studies in COVID-19 with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Hospices Civils de Lyon · Sites in France
Ages 8–18
Laboratoire de la Mer · Sites in France
Ages 15 days+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
782 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 57 · Phase 3 64 · Phase 4 4
First in 2016; this study’s year is marked. 499 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 130 across the 294 interventional studies, 298 across the 486 observational. Of the 530 that completed or were terminated, 39 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 782 have an industry lead sponsor. The 10 most frequent:
Hôpital Européen Marseille is the lead sponsor of 30 studies on the registry; 8 are open to participants now.
Hôpital Européen Marseille has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
8 of the studies in COVID-19 with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT07882186Assistance Publique - Hôpitaux de ParisAssessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region | 2027-03 |
| NCT03963622Unity Health TorontoCareful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19) | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 782 studies in COVID-19 with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to Assess of Long-term impact post COVID for patients and health care professionals.The patients and medical staff will be followed for 2 years in order to provide clinical and paraclinical data not yet published in the literature.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Subject to a measure for the protection of justice
Patients and medical staff having symptomatic COVID-19 infection confirmed (by RT-PCR or ELISA serology) or probable (CT criteria)
Diagnostic Test: Diagnostic Test: serology test for COVID-19
a serology test will be performed at M3
Evaluation of post-traumatic stress symptoms (Post traumatic Stress Disorder (PTSD) scale) at M3 for patients and caregivers
measure used to assess symptoms of post-traumatic stress disorder. Individuals should rate their experience with each of the 17 symptoms of PTSD on a scale of 1 to 5 (1 = not at all, 2 = a little, 3 = moderately, 4 = a little, and 5 = extremely) versus to a specific traumatic event
Time frame: 3 months
Evaluation of post-traumatic stress symptoms (PTSD scale) at M12 and M24 for patients and caregivers
Time frame: 12 and 24 months
Change from M3 in the score of the mental (MCS), physical (PCS) components and the scores of the individual domains of the questionnaire SF36 to M12 and M24 for the entire study population
Time frame: 12 and 24 months
% of patients presenting a positive result by ELISA serology (= without distinction of IgG, IgM and IgA)
Time frame: 3 months
Comparison of M0 chest CT results at each follow-up for the entire study population
Time frame: 24 months
Change from M3 score measuring anxiety (HAD-A) and depression score (HAD-D) to M12 and M24 for patients and caregivers.
HAD-A score measuring anxiety (example "I feel tense or nervous") and HAD-D score for depression (example "I have the impression of operating in slow motion"). * 7 or less: no symptoms * 8 to 10: doubtful symptomatology * 11 and more: definite symptomatology.
Time frame: 12 and 24 months
Change from M3 in the B-IPQ score at M12 and M24 for patients and caregivers.
The Brief Illness Perception Questionnaire (B-IPQ) includes 9 items that assess different components of "perception of the disease"( score 0 to 10 for each items)
Time frame: 12 and 24 months
Evaluation of the microbiotic signature according to the severity of the disease at M3, M6 and M12
Time frame: 6 and 12 months
Evaluation of the fatigue EVA score and quality of life (SF36) at M6 and M12
score from 0 to 10 (0 not tired, 10 max tired)
Time frame: 6 and 12 months
Plan to share: No
Ran from Aug 2020 to primary completion in Feb 2022, 17 months.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 17 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Aug 2022 → Feb 2022 and completion Oct 2022 → Feb 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital Européen Marseille